Literature DB >> 16819640

[Treatment of systemic sclerosis].

F H J van den Hoogen1.   

Abstract

Systemic sclerosis (SSc, scleroderma) is a multisystem disease with a bad prognosis. No drugs have been shown to cure this disease. In view of its pathogenesis, in which immune responses are presumed to play an important role, immune suppressive therapies are widely applied in the treatment of SSc. Recent placebo-controlled trials with cyclophosphamide in patients with SSc complicated by alveolitis, show a modest but significant difference in pulmonary function tests in favour for the cyclophosphamide treated group. Treatment with prostacyclin analogues and endothelin-1 receptor antagonists appear to stabilize pulmonary arterial hypertension, a thus far fatal complication of SSc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819640     DOI: 10.1007/s00393-006-0075-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  25 in total

1.  Relaxins: lessons and limitations.

Authors:  James R Seibold
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

2.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

Authors:  D Farge; J Passweg; J M van Laar; Z Marjanovic; C Besenthal; J Finke; H H Peter; F C Breedveld; W E Fibbe; C Black; C Denton; I Koetter; F Locatelli; A Martini; A V N Schattenberg; F van den Hoogen; L van de Putte; F Lanza; R Arnold; P A Bacon; S Bingham; F Ciceri; B Didier; J L Diez-Martin; P Emery; W Feremans; B Hertenstein; F Hiepe; R Luosujärvi; A Leon Lara; A Marmont; A M Martinez; H Pascual Cascon; C Bocelli-Tyndall; E Gluckman; A Gratwohl; A Tyndall
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

3.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

4.  Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

Authors:  D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger
Journal:  Ann Intern Med       Date:  2000-03-21       Impact factor: 25.391

5.  Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

Authors:  F H van den Hoogen; A M Boerbooms; A J Swaak; J J Rasker; H J van Lier; L B van de Putte
Journal:  Br J Rheumatol       Date:  1996-04

6.  High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.

Authors:  P J Clements; D E Furst; W K Wong; M Mayes; B White; F Wigley; M H Weisman; W Barr; L W Moreland; T A Medsger; V Steen; R W Martin; D Collier; A Weinstein; E Lally; J Varga; S Weiner; B Andrews; M Abeles; J R Seibold
Journal:  Arthritis Rheum       Date:  1999-06

Review 7.  D-penicillamine is not an effective treatment in systemic sclerosis.

Authors:  D E Furst; P J Clements
Journal:  Scand J Rheumatol       Date:  2001       Impact factor: 3.641

8.  Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

Authors:  S N C Liossis; A Bounas; A P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2006-02-20       Impact factor: 7.580

9.  Sitaxsentan therapy for pulmonary arterial hypertension.

Authors:  Robyn J Barst; David Langleben; Adaani Frost; Evelyn M Horn; Ronald Oudiz; Shelley Shapiro; Vallerie McLaughlin; Nicholas Hill; Victor F Tapson; Ivan M Robbins; Diane Zwicke; Benjamin Duncan; Richard A F Dixon; Lyn R Frumkin
Journal:  Am J Respir Crit Care Med       Date:  2003-11-20       Impact factor: 21.405

10.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.